Stock listing
Cambium Bio Ltd
Selected listing: CMB · ASX · AUD · AU
Cambium Bio Ltd (ASX:CMB), Health Technology. Latest release Sep 16, 2026: Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate…
- Ticker
- ASX:CMB
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- ASX
- Currency
- AUD
About Cambium Bio Ltd
The company focuses on developing innovative solutions in the biotechnology sector. Cambium Bio aims to advance its projects and enhance its presence in the market.
Latest news from Cambium Bio Ltd
Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease
September 16, 2026
Cambium Bio Secures A$10.85 Million Funding Package
September 15, 2026
FY26 Appendix 4E and Annual Report
August 28, 2026
Cambium Bio Raises A$1.0 Million via Placement
July 21, 2026
FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
April 23, 2026